Treatment of Hodgkin lymphoma: the past, present, and future

[1]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Munsell,et al.  NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. , 2007, Blood.

[3]  A. Rademaker,et al.  G‐CSF is not necessary to maintain over 99% dose–intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10‐year analysis , 2007, British journal of haematology.

[4]  A. Hart,et al.  Late cardiotoxicity after treatment for Hodgkin lymphoma. , 2007, Blood.

[5]  A. Horwich,et al.  Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. , 2007, Journal of the National Cancer Institute.

[6]  J. Rowe,et al.  Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. , 2007, Blood.

[7]  J. Delabie,et al.  Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma , 2007, Leukemia & lymphoma.

[8]  V. Diehl,et al.  Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  R. Greil,et al.  HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany. , 2006 .

[10]  C. Pascutto,et al.  Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up , 2006, Clinical Cancer Research.

[11]  S. Pileri,et al.  Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Juan F. García,et al.  Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. , 2006, Blood.

[13]  J. Raemaekers,et al.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  O. Casasnovas,et al.  Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2006, Blood.

[15]  A. Younes,et al.  Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. , 2006, Blood.

[16]  J. Wooldridge,et al.  Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy , 2006, Leukemia & lymphoma.

[17]  P. Gobbi,et al.  ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Maclennan,et al.  Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Hagenbeek,et al.  Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial. , 2005 .

[20]  H. Eich,et al.  Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  V. Diehl,et al.  Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Habermann,et al.  Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Gail,et al.  Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. , 2005, Journal of the National Cancer Institute.

[24]  H. Eich,et al.  Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Yan Liu,et al.  Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  V. Diehl,et al.  Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Andreeff,et al.  Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death , 2005, British journal of haematology.

[28]  J. Connors,et al.  Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Eich,et al.  Lymphocyte‐predominant and classical Hodgkin's lymphoma – comparison of outcomes , 2005, European journal of haematology. Supplementum.

[30]  V. Diehl,et al.  From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. , 2005, Blood.

[31]  S. Proctor,et al.  An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme , 2005, European journal of haematology. Supplementum.

[32]  R. Greil,et al.  Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin’s lymphoma: Results of the fourth interim analysis of the HD 11 trial of the GHSG , 2005 .

[33]  E. Noordijk,et al.  First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL) , 2005 .

[34]  A. Zelenetz,et al.  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.

[35]  P. Borchmann,et al.  The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. , 2004, Blood.

[36]  T. Portis,et al.  Epstein–Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway , 2004, Oncogene.

[37]  S. Lipsitz,et al.  Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Aggarwal,et al.  Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors , 2004, Clinical Cancer Research.

[39]  J. Crocker,et al.  Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Niedzwiecki,et al.  How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. D. Van den Abbeele,et al.  FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison , 2004, Leukemia & lymphoma.

[42]  Dirk Hasenclever,et al.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Hamilton-Dutoit,et al.  XIAP-mediated Caspase Inhibition in Hodgkin's Lymphoma–derived B Cells , 2003, The Journal of experimental medicine.

[44]  P. Mclaughlin,et al.  A pilot study of rituximab in patients with recurrent, classic Hodgkin disease , 2003, Cancer.

[45]  Jorge A. Almenara,et al.  The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. , 2003, Cancer research.

[46]  V. Diehl,et al.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.

[47]  J. Raemaekers,et al.  Involved-field radiotherapy for advanced Hodgkin's lymphoma. , 2003, The New England journal of medicine.

[48]  Y. Natkunam,et al.  Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. , 2003, Blood.

[49]  M Sieber,et al.  14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  L. Brochard,et al.  Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis , 2003, Critical care medicine.

[51]  V. Diehl,et al.  Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2003, Blood.

[52]  J. Connors,et al.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  V. Diehl,et al.  Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. , 2003, Blood.

[54]  Z. Miltényi,et al.  Hypothyroidism and Thyroiditis after Therapy for Hodgkin’s Disease , 2002, Acta Haematologica.

[55]  J. Friedberg,et al.  Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. , 2002, Blood.

[56]  M. Stovall,et al.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  T. Lister,et al.  ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  V. Diehl,et al.  Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. , 2002, The American journal of pathology.

[59]  A. Levis,et al.  Hodgkin's disease in the elderly: current status and future directions. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  Charles Enke,et al.  Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  S. Horning,et al.  Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  R. Fisher,et al.  Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  S. Sleijfer.  Bleomycin-induced pneumonitis. , 2001, Chest.

[64]  R. Greil,et al.  Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  V. Diehl,et al.  Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. , 2001, Cancer research.

[66]  H. Stein,et al.  Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. , 2001, Blood.

[67]  E. Alba,et al.  Secondary Prophylactic G-CSF (Filgrastim) Administration in Chemotherapy of Stage I and II Hodgkin's Lymphoma with ABVD , 2001, Leukemia & lymphoma.

[68]  H. Stein,et al.  Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. , 2000, Blood.

[69]  A. Hagenbeek,et al.  Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  T. Lister,et al.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  V. Diehl,et al.  Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[73]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[74]  R Peto,et al.  Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  W. Chan,et al.  Clonality in nodular lymphocyte-predominant Hodgkin's disease. , 1997, The New England journal of medicine.

[76]  S. Pileri,et al.  Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. , 1997, The New England journal of medicine.

[77]  G. Bonadonna,et al.  Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Pfreundschuh,et al.  Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease , 1995 .

[79]  R. Fanin,et al.  The Role of Granulocyte Colony-Stimulating Factor (Filgrastim) in Maintaining Dose Intensity during Conventional-Dose Chemotherapy with Abvd in Hodgkin's Disease , 1994, Tumori.

[80]  R Fischer,et al.  Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[81]  L. Dirix,et al.  Pulmonary toxicity and bleomycin , 1994, The Lancet.

[82]  A. Hagenbeek,et al.  A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Hagenbeek,et al.  Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  J. Matthews.  Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy , 1993, The Lancet.

[85]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[86]  K. Maclennan,et al.  British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. , 1991, British Journal of Cancer.

[87]  C. Haanen,et al.  Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  B. Hancock.  Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[89]  E. Jaffe,et al.  Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  A. Santoro,et al.  Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. , 1986, Annals of internal medicine.

[91]  G. Rosner,et al.  BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. , 1984, Annals of internal medicine.

[92]  C. Coltman,et al.  Comparison of adriamycin‐containing chemotherapy (MOP‐BAP) with MOPP‐bleomycin in the management of advanced Hodgkin‐s disease a southwest oncology group study , 1983, Cancer.

[93]  S. Rosenberg,et al.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  T. Lister,et al.  MVPP chemotherapy regimen for advanced Hodgkin's disease , 1978, British medical journal.

[95]  T. Mcelwain,et al.  A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. , 1977, British Journal of Cancer.

[96]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.

[97]  A. Stansfeld,et al.  Combination Chemotherapy in Generalized Hodgkin's Disease , 1970, British medical journal.

[98]  J. Raemaekers,et al.  Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. , 2007, International journal of radiation oncology, biology, physics.

[99]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[100]  A. Levis,et al.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.

[101]  H. Eich,et al.  A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  Michael Karin,et al.  The IKK NF-kappa B system: a treasure trove for drug development. , 2004, Nature reviews. Drug discovery.

[103]  K. Naresh,et al.  Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  Michael Karin,et al.  The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.

[105]  E. Yoshikawa,et al.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[106]  S. Grant,et al.  The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p 21 CIP 1 / WAF 1 1 , 2003 .

[107]  M. Björkholm,et al.  Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. , 2003, Haematologica.

[108]  V. Diehl,et al.  Treatment of relapsed CD 20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated : results of a phase 2 trial of the German Hodgkin Lymphoma Study Group , 2002 .

[109]  K. Uetsuka,et al.  Granulocyte colony-stimulating factor exacerbates the acute lung injury and pulmonary fibrosis induced by intratracheal administration of bleomycin in rats. , 2002, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[110]  Olker,et al.  A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE , 2000 .

[111]  A. Buck,et al.  Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography , 1998 .

[112]  R. Fisher,et al.  MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  J. Raemaekers,et al.  Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Cu , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  Flavio Crippa,et al.  Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[116]  J. Boyd,et al.  The treatment of Hodgkin's disease. , 1966, Guy's Hospital reports.